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Abstract: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor 
Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of 
panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed 
in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical 
studies have established a role for panitumumab in metastatic colorectal cancer (mCRC) refractory 
to multiple chemotherapeutic regimens. Based on these encouraging findings, panitumumab was 
approved by the US Food and Drug Administration for the treatment of patients with epidermal 
growth factor receptor-expressing mCRC refractory to fluoropyrimidine-, oxaliplatin-, and/or 
irinotecan-containing chemotherapeutic regimens. The improvement in progression free survival 
(PFS) and response rate (RR) produced by panitumumab monotherapy was significantly greater 
in patients with non mutated (wild-type) K-RAS than in those with mutant K-RAS. Therefore 
implementing routine K-RAS screening and limiting the use of EGFR inhibitors to patients with 
wild-type K-RAS appears the better strategy for select only the patients who could benefit from 
the therapy with panitumumab and also may have the potential for cost savings. The purpose of 
this review was to evaluate the patient-related, disease-related and economic-related evidence for 
the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice.
Keywords: colorectal cancer, EGFR; K-RAS, panitumumab
Core  Evidence  clinical  impact  summary  for  [Panitumumab  for metastatic 
colorectal cancer]
Outcome measure Evidence Implications
Disease-oriented  
evidence
Phase i–ii studies Panitumumab was well tolerated, 
and no human anti-human  
antibody formation or infusion-related 
reactions were observed.  
Moreover, the use of panitumumab 
increased overall response  
rate and seemed to improve  
PFS and OS.
Panitumumab was evaluated in 
phase iii trials in patients with 
relapsed or refractory metastatic 
CRC.
Phase iii Panitumumab significantly 
improved overall response rate,  
PFR and OS in mCRC pretreated  
patients.
Panitumumab monotherapy 
received FDA approval for the 
treatment of metastatic colorectal 
cancer with disease progression 
while receiving or after receiving 
fluoropyrimidine, oxaliplatin, and 
irinotecan chemotherapy regimens.
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Introduction
The most recent improvements in the treatment of mCRC 
have derived from the development of targeted therapy 
toward cell surface receptors and their   associated   intracellular 
second-messenger systems. Targeted therapy against tumors 
is an   attractive therapeutic strategy in the treatment of human 
malignancies, complementing currently available chemo-
therapeutic agents and avoiding overlapping toxicities, as 
well as potentially improving clinical response rates and 
patient survival.
Recently, EGFR has been validated as a therapeutic 
target in several human tumors, including colorectal cancer 
(CRC).
In fact, overexpression or dysregulation of EGFR has 
been reported in several solid tumors and it is associated 
with tumor cell proliferation, invasion, distant metastasis, 
angiogenesis, antiapoptosis, and resistance to chemotherapy 
or radiation therapy. In CRC, EGFR is overexpressed in 
60%–80% of tumors, and the extent of EGFR   expression has 
been shown to positively correlate with a poor prognosis.1,2
The EGFR-targeted monoclonal antibodies block the 
interaction between a ligand and the extracellular binding 
domain of EGFR, inhibiting both phosphorylation and activa-
tion of EGFR-associated kinases (such as epidermal growth 
factor (EGF), transforming growth factor-α (TGF-α)), 
causing internalization of the receptor, inhibition of cellular 
growth, induction of apoptosis, and decreased production of 
growth factors (such as proinflammatory cytokines, vascular 
endothelial growth factor (VEGF)).3,4
Both monoclonal antibodies and small molecules 
  inhibitors of the tyrosine-kinase of EGFR have been 
  evaluated in the treatment of solid tumors, including CRC, 
non-small cell lung cancer, squamous cell carcinoma of 
the head and neck.5 Currently, two monoclonal   antibodies 
targeting the EGFR, cetuximab and panitumumab, are 
  commercially available for the treatment of mCRC.
Panitumumab
Panitumumab, formerly known as ABX-EGF, is a fully human 
IgG2 monoclonal antibody targeting EGFR and   developed 
using XenoMouse (Abgenix, Fremont, CA, USA) technology. 
In vitro, panitumumab has been found to have high binding 
affinity to EGFR, competitively   blocking   binding of EGF 
and TGF-α to the receptor and leading to internalization of 
the receptor-antibody complex. This   prevents   ligand-induced 
EGFR-tyrosine   autophosphorylation and subsequent activa-
tion of key downstream   signaling   molecules involved in 
carcinogenesis. This leads to   antitumor effects by promot-
ing apoptosis and inhibiting cell   proliferation, growth and 
angiogenesis.6,7
Since it is the first fully human monoclonal antibody, 
the risk of hypersensitivity reactions with panitumumab 
is reduced, and this may be important for long-term 
administration.8
(Continued)
Patient-oriented evidence
K-RAS Clinical efficacy of panitumumab  
therapy is restricted to patients with 
wild-type K-RAS tumors.There was 
no evidence of benefit in patients with 
mutated K-RAS tumors.
K-RAS genotyping of tumors should 
be strongly considered to select 
patients being treated with 
panitumumab. 
Skin Toxicity The development of skin toxicity  
during panitumumab monotherapy  
has been significantly linked  
with higher response rate and longer 
survival.
Skin toxicity cannot be used to 
select patients and it could be useful 
in the clinical practice to identify 
patients who may derive greater 
benefit from panitumumab 
treatment.
Economic evidence 
Role of K-RAS  
testing in clinical 
practice.
Screening could cost several thousand 
dollars per patient and still result in a 
lower overall cost of care, based on 
very conservative estimates of the cost 
reduction associated with treatment 
avoidance in patients with K-RAS 
mutations. 
implementing routine K-RAS 
screening and limiting the 
use of EGFR inhibitors to patients 
with wild-type K-RAS actually 
appears the better strategy for 
selecting only the patients who 
could benefit from the therapy with 
panitumumab and also may have the 
potential for cost savings.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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Panitumumab in colorectal cancer
Panitumumab induces cell-cycle arrest in the G0–G1 
interphase, whereas cetuximab causes arrest in the G1 
phase. Unlike cetuximab, panitumumab does not induce 
  antibody-dependent cellular cytotoxicity.9,10
Panitumumab was initially studied as a single agent in 
previously treated patients with metastatic colorectal cancer 
and showed promising antitumor responses and minimal 
adverse effects, offering an alternative to cetuximab as a 
second-or third-line treatment option for patients with meta-
static colorectal cancer who have failed prior therapies.
Disease-oriented evidence
Phase i and ii studies
Panitumumab has been evaluated in clinical trials both as 
monotherapy and in combination with other agents for the 
treatment of solid tumors, including colorectal and kidney 
cancer (Table 1).11
A phase I trial by Figlin et al12 using doses ranging from 
0.1 mg/kg up to 2.5 mg/kg was performed in 43 patients 
with several tumor types (renal = 10; prostate = 3; non-
small-cell lung cancer = 7; pancreatic = 3; esophageal = 3 
and CRC = 7). Patients received up to 4 weekly doses, and 
those experiencing response or stable disease (SD) were 
eligible to continue to receive treatment every other week 
for 6 additional months or until disease progression. Biologic 
activity was seen even with low doses, including one patient 
with esophageal cancer treated with the lowest dose that had 
SD for 7 months. A partial response (PR) of 10 months was 
seen in one patient with CRC treated with 2.5 mg/kg. The 
incidence of skin rash in patients receiving 2.0 or 2.5 mg/kg 
approached 100%. Overall, panitumumab was well tolerated 
and no allergic reactions, infusion-related or serious adverse 
events were observed.
Weiner et al13 updated these data in with another 
phase I trial. 96 patients were enrolled and treated 
(CRC = 39, lung = 14, pancreatic = 3, prostate = 21, 
renal = 15,   esophageal = 3 and anal cancer = 1). Sequen-
tial cohorts were enrolled to receive four infusions of 
  panitumumab monotherapy at different dose levels ranging 
from 0.01 to 5.0 mg/kg once per week, 6.0 mg/kg every 
2 weeks and 9.0 mg/kg every 3 weeks. Grade 3 or 4 related 
adverse events were noted in 10% of patients, with grade 3 
skin-related effects being the most frequent (7% of patients). 
No maximally tolerated dose was reached and no infusion-
related reactions were observed. Furthermore, five of the 
39 CRC patients achieved a PR.
After the favourable response rate observed among 
patients with CRC participating in these studies, panitumumab 
was evaluated in phase II trials in patients with relapsed or 
refractory metastatic CRC (Table 1).
One study included patients who had failed therapy with 
a fluoropyrimidine (with or without leucovorin) and either 
irinotecan or oxaliplatin, or both.14 Assessment based on level 
of EGFR expression was also carried out and patients were 
enrolled into 2 cohorts. Patient cohorts were determined by 
levels of EGFR expression. Cohort A (n = 105) consisted 
of patients with 2+ or 3+ EGFR over-expression in $10% 
of tumor cells. Cohort B (n = 43) included patients with 
the sum of 1+, 2+, and 3+ EGFR staining found in $10% 
of tumor cells, but with the sum of 2+ and 3+ in ,10% 
of tumor cells. Patients received panitumumab 2.5 mg/kg 
weekly for 8 weekly cycles. Overall, 15 PR were reported: 
11 (10%) in cohort A and 4 (9%) in cohort B. Median time 
to disease progression and median survival were 3.4 months 
and 10 months, respectively, for cohort A, and 2.1 months 
and 9.4 months, respectively, for cohort B.
In another phase II trial performed by Berlin et al15 
panitumumab monotherapy was evaluated in patients with 
mCRC failing at least two previous regimens with a fluoro-
pyrimidine, irinotecan, and oxaliplatin. Panitumumab was 
administered at 6 mg/kg intravenously every 2 weeks until 
disease progression occurred. Primary endpoints were: 
objective RR; response duration; PFS: and survival time. 
The secondary endpoint was tolerability. Assessment based 
on level of EGFR expression was also carried out, and all 
patients were required to have EGFR staining of $10% 
tumor cells on immunohistochemistry (IHC).
An interim analysis in May 2005 included 39 patients 
eligible for efficacy evaluation following $20 weeks 
of treatment and 91 patients available for tolerability 
analysis after receiving at least 1 dose of panitumumab. 
At week 16, 3 (8%) patients had PR, 8 patients (21%) 
achieved SD, and 19 patients (49%) experienced disease 
progression. Nine patients (22%) were not assessable. 
Integument toxicities included skin (96%), nail (30%), 
chelitis (7%), and hair (5%). Eye toxicity occurred in 
85% of patients; diarrhea, in 27% (3 with grade 3); and 
hypomagnesemia, in 12% (3 with grade 3 or grade 4). 
Grade 3 hypersensitivity reaction occurred in 1 patient 
and resolved with treatment. This study plans a total 
enrollment of 300 patients.15
Moreover, the results of another study showed, in patients 
with low or negative EGFR staining, a response rate of 
approximately 5%.16
Panitumumab was also evaluated in combination with 
fluorouracil/leucovorin and irinotecan (IFL or FOLFIRI Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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  regimens) for first-line treatment of metastatic colorectal 
cancer. Part 1 of the study included patients who received 
panitumumab with IFL (n = 19), and part 2 included 
patients who received panitumumab with FOLFIRI (n = 24). 
  Eligibility criteria included no prior chemotherapy and EGFR 
positivity ($10%). Panitumumab was administered weekly 
at a dose of 2.5 mg/kg over one hour. Due to unacceptable 
toxicity in part 1 (58% grade 3 or grade 4 diarrhea), the study 
was modified to evaluate panitumumab in combination with 
FOLFIRI (part 2).
No complete responses were observed. The investigators 
reported 9 (47%) patients with PR and 5 (26%) with SD 
for part 1 of the study. Among patients enrolled in part 2, 
there were 8 (33%) with PR and 11 (46%) with SD. Median 
PFS was 5.6 months and 10.9 months for parts 1 and 2, 
  respectively. Median survival for patients enrolled in part 1 
was 16.8 months. Survival data were not available for patients 
enrolled in part 2; however, 23 out of 24 patients were alive 
at the time of analysis.17
Phase iii studies
Based on the encouraging clinical outcomes of the above 
mentioned phase II trials, a pivotal, randomized, con-
trolled phase III trial conducted in Europe, Australia, and 
Canada was performed, in order to compare panitumumab 
6 mg/kg intravenously every 2 weeks plus best supportive 
care (BSC) versus best supportive care alone. The aim of 
this study was to show the significant difference in PFS. 
A total of 463 patients were enrolled (n = 231 receiv-
ing panitumumab plus BSC and n = 232 receiving BSC 
alone). Eligible patients had metastatic colorectal cancer 
($1% EGFR-positive tumor cells) and documented pro-
gressive disease during treatment or within 6 months of 
completing treatment with a fluoropyrimidine, irinotecan, 
and oxaliplatin.
Patients in the best supportive care group experiencing 
progressive disease could receive panitumumab in a cross-
over study. This study was designed to be able to detect a 
33% difference in PFS, but the results far exceeded this 
with a risk reduction of 46%, statistically significant with 
P , 0.000000001. The overall response rate was 36% 
versus 10% (control) with a median duration of response 
of 17 weeks in the control arm. At 6 months, PFS was 18% 
versus 5% and this difference was maintained at 8 months: 
10% versus 4%. Although no difference has been noted in 
overall survival, this is likely to have been confounded by 
the fact that 75% of those on the best supportive care arm 
crossed over to panitumumab with impressive results. Of the 
174 patients who crossed over to the treatment arm, there was 
a 9% PR and 32% with SD.
The most common toxicities reported were skin  toxicities, 
hypomagnesemia, and diarrhoea. Skin reaction occurred 
in 90% of patients receiving panitumumab and consistent 
with other reports, an association between severe rash and 
greater clinical efficacy was observed. As expected with 
fully human antibodies, panitumumab had a low frequency of 
  infusion-related reactions and no antibody formation. An open-
label extension study showed similar results for those patients 
initially receiving best supportive care who later received 
panitumumab therapy. Based on these results,   panitumumab 
monotherapy received FDA approval for the treatment of 
metastatic colorectal cancer with disease   progression while 
receiving or after receiving fluoropyrimidine, oxaliplatin, and 
irinotecan chemotherapy regimens.18,19
The role of panitumumab in combination with anti-
angiogenic drugs has also been explored in a randomized 
phase III study (Panitumumab Advanced Colorectal Cancer 
Evaluation, (PACCE)). In this trial patients with mCRC 
were randomly assigned for first-line treatment within 
each   chemotherapy cohort (823 patients oxaliplatin- and 
230   irinotecan-based) to bevacizumab and chemotherapy 
with or without panitumumab 6 mg/kg every 2 weeks. 
Most patients received oxaliplatin-based chemotherapy. 
The   primary end-point was PFS within the oxaliplatin cohort. 
The results of the study were negative, as the combination of 
panitumumab with bevacizumab and chemotherapy resulted 
in a decrease of PFS and in excessive toxicity, particularly 
diarrhoea, infections and pulmonary embolism. The results 
were consistent in both the oxaliplatin and irinotecan cohorts. 
Moreover, as demonstrated previously, the triple combination 
did not provide additional benefit in the K-RAS wild-type 
population treated with panitumumab.20
Recently, two large, randomized, phase III trials, were 
presented at 2009 Joint ECCO/ESMO Multidisciplinary 
Congress in Berlin, Germany.21,22
The PRIME trial was a multicenter, randomized, phase III 
study performed by Douillard et al21 in order to analyze the 
safety and efficacy of first-line treatment with panitumumab 
plus FOLFOX versus FOLFOX alone in mCRC according 
to K-RAS status.
Patients were randomized 1:1 to receive 6 mg/kg of 
panitumumab plus FOLFOX every 2 weeks (Arm 1) versus 
FOLFOX alone (Arm 2). The primary endpoint was PFS. 
The study randomized a total of 1183 patients, with 593 in 
Arm 1 and 590 in Arm 2. K-RAS results were obtained for 
93% of patients: 60% were K-RAS wild-type and 40% were Core Evidence 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
67
Panitumumab in colorectal cancer
T
a
b
l
e
 
2
 
S
u
m
m
a
r
y
 
o
f
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
r
e
g
a
r
d
i
n
g
 
p
a
n
i
t
u
m
u
m
a
b
P
r
o
t
o
c
o
l
 
I
D
s
T
i
t
l
e
D
e
s
i
g
n
S
t
a
t
u
s
T
r
i
a
l
 
d
e
s
c
r
i
p
t
i
o
n
C
T
R
U
-
P
i
C
C
O
L
O
-
 
M
O
-
0
5
-
7
2
8
9
P
h
a
s
e
 
i
i
i
 
R
a
n
d
o
m
i
z
e
d
 
S
t
u
d
y
 
o
f
 
i
r
i
n
o
t
e
c
a
n
 
 
H
y
d
r
o
c
h
l
o
r
i
d
e
 
w
i
t
h
 
v
e
r
s
u
s
 
w
i
t
h
o
u
t
 
 
P
a
n
i
t
u
m
u
m
a
b
 
o
r
 
C
y
c
l
o
s
p
o
r
i
n
e
 
i
n
 
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
F
l
u
o
r
o
u
r
a
c
i
l
-
R
e
s
i
s
t
a
n
t
 
 
A
d
v
a
n
c
e
d
 
o
r
 
M
e
t
a
s
t
a
t
i
c
 
C
o
l
o
r
e
c
t
a
l
 
C
a
n
c
e
r
P
h
a
s
e
 
i
i
i
,
 
R
a
n
d
o
m
i
z
e
d
A
c
t
i
v
e
A
r
m
 
i
:
 
P
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
 
i
r
i
n
o
t
e
c
a
n
 
o
n
 
d
a
y
 
1
.
 
A
r
m
 
i
i
:
 
P
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
 
i
r
i
n
o
t
e
c
a
n
 
o
n
 
d
a
y
 
1
 
a
n
d
 
o
r
a
l
 
c
y
c
l
o
s
p
o
r
i
n
e
 
t
h
r
e
e
 
t
i
m
e
s
 
a
 
d
a
y
 
o
n
 
d
a
y
s
 
1
–
3
.
 
A
r
m
 
i
i
i
:
 
P
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
 
p
a
n
i
t
u
m
u
m
a
b
 
f
o
l
l
o
w
e
d
 
b
y
 
i
r
i
n
o
t
e
c
a
n
 
o
n
 
d
a
y
 
1
.
 
S
i
n
g
l
e
-
a
g
e
n
t
 
p
a
n
i
t
u
m
u
m
a
b
 
m
a
y
 
b
e
 
c
o
n
t
i
n
u
e
d
 
d
u
r
i
n
g
 
b
r
e
a
k
s
 
i
n
 
c
h
e
m
o
t
h
e
r
a
p
y
 
t
r
e
a
t
m
e
n
t
.
2
0
0
8
0
7
6
3
A
S
P
E
C
C
T
:
 
A
 
S
t
u
d
y
 
o
f
 
P
a
n
i
t
u
m
u
m
a
b
 
 
E
f
fi
c
a
c
y
 
a
n
d
 
S
a
f
e
t
y
 
C
o
m
p
a
r
e
d
 
t
o
 
 
C
e
t
u
x
i
m
a
b
 
i
n
 
S
u
b
j
e
c
t
s
 
w
i
t
h
 
K
R
A
S
 
 
w
i
l
d
-
T
y
p
e
 
M
e
t
a
s
t
a
t
i
c
 
C
o
l
o
r
e
c
t
a
l
 
C
a
n
c
e
r
P
h
a
s
e
 
i
i
i
,
 
R
a
n
d
o
m
i
z
e
d
A
c
t
i
v
e
T
h
e
 
p
r
i
m
a
r
y
 
o
b
j
e
c
t
i
v
e
 
o
f
 
t
h
i
s
 
s
t
u
d
y
 
i
s
 
t
o
 
c
o
m
p
a
r
e
 
t
h
e
 
e
f
f
e
c
t
 
o
f
 
p
a
n
i
t
u
m
u
m
a
b
 
v
e
r
s
u
s
 
c
e
t
u
x
i
m
a
b
 
o
n
 
o
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
(
O
S
)
 
f
o
r
 
c
h
e
m
o
r
e
f
r
a
c
t
o
r
y
 
m
e
t
a
s
t
a
t
i
c
 
c
o
l
o
r
e
c
t
a
l
 
c
a
n
c
e
r
 
(
m
C
R
C
)
 
a
m
o
n
g
 
s
u
b
j
e
c
t
s
 
w
i
t
h
 
w
i
l
d
-
t
y
p
e
 
K
i
r
s
t
e
n
 
r
a
t
 
S
a
r
c
o
m
a
-
2
 
v
i
r
u
s
 
(
K
R
A
S
)
 
t
u
m
o
r
s
.
2
0
0
6
0
1
4
1
S
P
i
R
i
T
T
 
–
 
S
e
c
o
n
d
-
L
i
n
e
 
P
a
n
i
t
u
m
u
m
a
b
 
 
i
r
i
n
o
t
e
c
a
n
 
T
r
e
a
t
m
e
n
t
 
T
r
i
a
l
P
h
a
s
e
 
i
i
,
 
R
a
n
d
o
m
i
z
e
d
A
c
t
i
v
e
A
r
m
 
1
:
 
F
O
L
F
i
R
i
 
+
 
P
a
n
i
t
u
m
u
m
b
 
A
r
m
 
2
:
 
F
O
L
F
i
R
i
 
+
 
B
e
v
a
c
i
z
u
m
a
b
N
U
-
0
7
i
4
P
h
a
s
e
 
i
i
 
R
a
n
d
o
m
i
z
e
d
 
S
t
u
d
y
 
o
f
 
E
r
l
o
t
i
n
i
b
 
H
y
d
r
o
c
h
l
o
r
i
d
e
 
a
n
d
 
P
a
n
i
t
u
m
u
m
a
b
 
w
i
t
h
 
v
e
r
s
u
s
 
w
i
t
h
o
u
t
 
i
r
i
n
o
t
e
c
a
n
 
 
H
y
d
r
o
c
h
l
o
r
i
d
e
 
a
s
 
S
e
c
o
n
d
-
L
i
n
e
 
T
h
e
r
a
p
y
 
i
n
 
P
a
t
i
e
n
t
s
 
 
w
i
t
h
 
M
e
t
a
s
t
a
t
i
c
 
C
o
l
o
r
e
c
t
a
l
 
C
a
n
c
e
r
P
h
a
s
e
 
i
i
,
 
R
a
n
d
o
m
i
z
e
d
A
c
t
i
v
e
A
r
m
 
i
:
 
e
r
l
o
t
i
n
i
b
 
o
n
c
e
 
d
a
i
l
y
 
o
n
 
d
a
y
s
 
1
–
1
4
,
 
p
a
n
i
t
u
m
u
m
a
b
 
o
n
 
d
a
y
 
1
,
 
a
n
d
 
i
r
i
n
o
t
e
c
a
n
.
 
o
n
 
d
a
y
 
1
.
 
T
r
e
a
t
m
e
n
t
 
r
e
p
e
a
t
s
 
e
v
e
r
y
 
2
 
w
e
e
k
s
 
i
n
 
t
h
e
 
a
b
s
e
n
c
e
 
o
f
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
o
r
 
u
n
a
c
c
e
p
t
a
b
l
e
 
t
o
x
i
c
i
t
y
.
A
r
m
 
i
i
:
 
e
r
l
o
t
i
n
i
b
 
o
n
c
e
 
d
a
i
l
y
 
o
n
 
d
a
y
s
 
1
–
1
4
 
a
n
d
 
p
a
n
i
t
u
m
u
m
a
b
 
o
n
 
d
a
y
 
1
.
 
T
r
e
a
t
m
e
n
t
 
r
e
p
e
a
t
s
 
e
v
e
r
y
 
2
 
w
e
e
k
s
 
i
n
 
t
h
e
 
a
b
s
e
n
c
e
 
o
f
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
 
o
r
 
u
n
a
c
c
e
p
t
a
b
l
e
 
t
o
x
i
c
i
t
y
.
 
U
p
o
n
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
,
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
 
i
r
i
n
o
t
e
c
a
n
 
h
y
d
r
o
c
h
l
o
r
i
d
e
 
a
s
 
i
n
 
A
r
m
 
i
.
A
r
m
 
i
i
i
:
 
P
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
 
e
r
l
o
t
i
n
i
b
 
a
n
d
 
p
a
n
i
t
u
m
u
m
a
b
 
a
s
 
i
n
 
A
r
m
 
i
i
.
2
0
0
7
0
5
0
9
P
E
A
K
:
 
A
 
P
h
a
s
e
 
2
 
S
t
u
d
y
 
o
f
 
P
a
n
i
t
u
m
u
m
a
b
 
P
l
u
s
 
 
m
F
O
L
F
O
X
6
 
v
s
 
B
e
v
a
c
i
z
u
m
a
b
 
P
l
u
s
 
m
F
O
L
F
O
X
6
 
 
f
o
r
 
F
i
r
s
t
 
L
i
n
e
 
T
r
e
a
t
m
e
n
t
 
o
f
 
M
e
t
a
s
t
a
t
i
c
 
C
o
l
o
r
e
c
t
a
l
 
 
C
a
n
c
e
r
 
S
u
b
j
e
c
t
s
 
w
i
t
h
 
w
i
l
d
-
T
y
p
e
 
K
R
A
S
 
T
u
m
o
r
s
P
h
a
s
e
 
i
i
A
c
t
i
v
e
T
h
e
 
p
r
i
m
a
r
y
 
o
b
j
e
c
t
i
v
e
 
o
f
 
t
h
i
s
 
s
t
u
d
y
 
i
s
 
t
o
 
e
s
t
i
m
a
t
e
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
e
f
f
e
c
t
 
o
n
 
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
P
F
S
)
 
o
f
 
p
a
n
i
t
u
m
u
m
a
b
 
r
e
l
a
t
i
v
e
 
t
o
 
b
e
v
a
c
i
z
u
m
a
b
 
i
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
m
F
O
L
F
O
X
6
 
c
h
e
m
o
t
h
e
r
a
p
y
 
a
s
 
fi
r
s
t
-
l
i
n
e
 
t
h
e
r
a
p
y
 
i
n
 
s
u
b
j
e
c
t
s
 
w
i
t
h
 
t
u
m
o
r
s
 
e
x
p
r
e
s
s
i
n
g
 
w
i
l
d
-
t
y
p
e
 
K
R
A
S
,
 
u
n
r
e
s
e
c
t
a
b
l
e
 
m
C
R
C
.
0
8
-
2
8
7
P
a
n
i
t
u
m
u
m
a
b
 
i
n
 
C
e
t
u
x
i
m
a
b
 
 
R
e
f
r
a
c
t
o
r
y
 
K
R
A
S
 
w
i
l
d
-
T
y
p
e
 
 
C
o
l
o
r
e
c
t
a
l
 
C
a
n
c
e
r
P
h
a
s
e
 
i
i
A
c
t
i
v
e
T
h
e
 
p
u
r
p
o
s
e
 
o
f
 
t
h
i
s
 
r
e
s
e
a
r
c
h
 
s
t
u
d
y
 
i
s
 
t
o
 
l
e
a
r
n
 
w
h
e
t
h
e
r
 
p
a
n
i
t
u
m
u
m
a
b
 
h
e
l
p
s
 
t
r
e
a
t
 
c
o
l
o
r
e
c
t
a
l
 
c
a
n
c
e
r
 
i
n
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
h
o
 
h
a
v
e
 
n
o
t
 
r
e
s
p
o
n
d
e
d
 
t
o
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
c
e
t
u
x
i
m
a
b
.
T
T
D
-
0
8
-
0
4
S
a
f
e
t
y
 
a
n
d
 
E
f
fi
c
a
c
y
 
S
t
u
d
y
 
o
f
 
F
O
L
F
O
X
4
 
+
 
P
a
n
i
t
u
m
u
m
a
b
 
v
s
 
F
O
L
F
i
R
i
 
+
 
P
a
n
i
t
u
m
u
m
a
b
 
 
i
n
 
S
u
b
j
e
c
t
s
 
w
T
 
K
R
A
S
 
C
o
l
o
r
e
c
t
a
l
 
 
C
a
n
c
e
r
 
a
n
d
 
L
i
v
e
r
-
o
n
l
y
 
M
e
t
a
s
t
a
s
e
s
P
h
a
s
e
 
i
i
A
c
t
i
v
e
T
h
e
 
p
u
r
p
o
s
e
 
o
f
 
t
h
e
 
s
t
u
d
y
 
i
s
 
t
o
 
e
v
a
l
u
a
t
e
 
t
h
e
 
e
f
fi
c
a
c
y
 
a
n
d
 
s
a
f
e
t
y
 
o
f
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
o
f
 
P
a
n
i
t
u
m
u
m
a
b
 
w
i
t
h
 
F
O
L
F
O
X
4
 
C
h
e
m
o
t
h
e
r
a
p
y
 
o
r
 
P
a
n
i
t
u
m
u
m
a
b
 
w
i
t
h
 
F
O
L
F
i
R
i
 
C
h
e
m
o
t
h
e
r
a
p
y
 
i
n
 
S
u
b
j
e
c
t
s
 
w
i
t
h
 
w
i
l
d
-
 
T
y
p
e
 
K
R
A
S
 
C
o
l
o
r
e
c
t
a
l
 
C
a
n
c
e
r
 
a
n
d
 
l
i
v
e
r
-
o
n
l
y
 
M
e
t
a
s
t
a
s
e
s
.
B
r
U
O
G
-
C
R
-
2
1
8
P
a
n
i
t
u
m
u
m
a
b
 
a
n
d
 
B
e
v
a
c
i
z
u
m
a
b
 
M
a
i
n
t
e
n
a
n
c
e
 
A
f
t
e
r
 
 
F
i
r
s
t
-
L
i
n
e
 
F
O
L
F
O
X
-
B
e
v
a
c
i
z
u
m
a
b
 
f
o
r
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
 
A
d
v
a
n
c
e
d
 
C
o
l
o
r
e
c
t
a
l
 
C
a
n
c
e
r
 
w
i
t
h
 
w
i
l
d
-
T
y
p
e
 
R
a
s
P
h
a
s
e
 
i
i
A
c
t
i
v
e
B
e
v
a
c
i
z
u
m
a
b
 
g
i
v
e
n
 
a
t
 
7
.
5
 
m
g
/
k
g
.
 
e
v
e
r
y
 
3
 
w
e
e
k
s
 
u
n
t
i
l
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
.
 
P
a
n
i
t
u
m
u
m
a
b
 
g
i
v
e
n
 
a
t
 
9
 
m
g
/
k
g
.
 
e
v
e
r
y
 
3
 
w
e
e
k
s
 
u
n
t
i
l
 
d
i
s
e
a
s
e
 
p
r
o
g
r
e
s
s
i
o
n
.
 
P
r
i
m
a
r
y
 
O
b
j
e
c
t
i
v
e
:
 
T
o
 
d
e
t
e
r
m
i
n
e
 
t
h
e
 
s
a
f
e
t
y
 
o
f
 
e
v
e
r
y
 
3
 
w
e
e
k
 
p
a
n
i
t
u
m
u
m
a
b
 
a
n
d
 
b
e
v
a
c
i
z
u
m
a
b
 
a
s
 
m
a
i
n
t
e
n
a
n
c
e
 
t
h
e
r
a
p
y
 
f
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
m
e
t
a
s
t
a
t
i
c
 
c
o
l
o
r
e
c
t
a
l
 
c
a
n
c
e
r
.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
68
Berardi et al
mutant. Wild-type K-RAS patients had a median PFS and 
response rate of 9.6 months and 55% in Arm 1, and 8 months 
and 48% in Arm 2, respectively.
Patients with mutated K-RAS had a median PFS of 
7.3 months in Arm 1 and 8.8 months in Arm 2. Moreover, 
response rate was improved in patients with Wild-type K-RAS 
tumors (55% vs 48%) and at interim analysis, OS seemed to 
be significantly improved in patients with Wild-type K-RAS 
tumors, although additional follow-up is required. Adverse 
events were similar across the two arms except for those that 
were associated with anti-EGFR therapy. Final results con-
firmed the importance of K-RAS as a predictive biomarker 
in the setting of first-line mCRC treatment with EGFR 
inhibitors.21
The second study, performed by Peeters et al was a ran-
domized, phase III study that evaluated the efficacy and safety 
of panitumumab with fluorouracil, leucovorin, and irinotecan 
(FOLFIRI) versus FOLFIRI alone as   second-line treatment 
for mCRC. Patients enrolled in the study were   randomized to 
receive panitumumab 6 mg/kg every 2 weeks plus   FOLFIRI 
(Arm 1) versus FOLFIRI alone (Arm 2). Patients had metastatic 
colorectal adenocarcinoma;   documented   disease progression 
6 months or less after 1 prior therapy with fluoropyrimidine 
for mCRC, and ECOG score of 0–2. The evaluation of PFS 
and OS by K-RAS mutational status were the primary end-
points in the study. A total of 1186 patients were randomized 
(Arm 1 = 591; Arm 2 = 595). Of all patients, 1803 (91%) were 
evaluable for K-RAS, with 598 (55%) being wild-type and 485 
(45%) mutated. PFS was longer in wild-type K-RAS patients 
who were in Arm 1 versus Arm 2 (5.9 vs 3.9 months), but 
was similar in K-RAS mutated patients (5.0 vs 4.9 months). 
A similar trend was seen with OS in wild-type and mutated 
patients when Arm 1 was compared to Arm 2 (wild-type, 14.5 
vs 12.5 months; mutated, 11.8 vs 11.1 months). With regard 
to safety, panitumumab was well-tolerated with a manageable 
toxicity profile.22
Ongoing clinical trials
The study of panitumumab in CRC proceeds in a number 
of ongoing clinical trials. Current studies under way are 
evaluating panitumumab in combination with other chemo-
therapeutic drugs or with novel agents that have to come into 
common clinical practice. These trials will further define the 
role of panitumumab in CRC (Table 2).23
Patient-oriented evidence
EGFR expression
Due to the mechanism of action of panitumumab, 
positive EGFR protein expression, as determined by 
immunohistochemistry (IHC), was initially selected as an 
entry criterion for several studies evaluating EGFR inhibi-
tors. In this setting, data on the use of EGFR expression 
as a predictive biomarker of response to panitumumab 
therapy, showed controversial results. Two trials revealed a 
positive correlation between EGFR expression and response 
to panitumumab. In the first, Meropol et al24 enrolled 100 
patients with metastatic colorectal cancer (mCRC) to evalu-
ate panitumumab as monotherapy after failure of treatment 
with fluoropyrimidine plus irinotecan or oxaliplatin or both. 
Patients were eligible if $10% of the tumor cells had EGFR 
overexpression of 2+ or 3+ by IHC. 13% of patients had a 
PR, and their tumor cells had 3+ EGFR expression; 39% of 
patients had a SD. Furthermore, panitumumab monotherapy 
was also evaluated in 300 patients with mCRC enrolled in 
a phase II trial after a disease progression despite treatment 
with fluoropyrimidine, irinotecan, and oxaliplatin-based 
chemotherapy. One of the inclusion criteria, was EGFR 
staining of $10% tumor cells on IHC. 8% of patients had 
PR, 21% achieved SD, and   disease progression was seen in 
49% of patients.15
Controversial data were reported by Malik and Hecht in 
two separate trials.24,25
Malik et al conducted a phase II study enrolling two 
cohorts of patients with mCRC who failed chemotherapeu-
tic regimens containing fluoropyrimidine plus irinotecan, 
oxaliplatin, or both.14 Cohort A consisted of patients with 
2+ or 3+ EGFR over-expression in $10% of tumor cells 
and cohort B included patients with the sum of 2+ and 
3+ in ,10% of tumor cells. PR was observed in 10% of 
patients (cohort A, 10%; cohort B, 9%). Overall median 
time to disease progression was 2.5 months (95% CI, 
2–4) (cohort A, 3.4 months (95% CI, 2–4); cohort B, 
2.1 months (95% CI, 2–4.5). Overall median survival time 
was 9.4 months (95% CI, 6.6–10.6) (cohort A, 10 months 
[95% CI, 6.2–11]); cohort B, 9.4 months [95% CI, 6–10.6]). 
Although no statistical analysis was performed to evaluate 
the differences between low and high EGFR-expressing 
tumors the response rates, time to disease progression, and 
survival time appeared similar irrespective of the level of 
EGFR expression.
Hecht et al conducted a phase II trial to assess response 
rates in patients with low (1%–9% of tumor cells) or negative 
(,1% of tumor cells) EGFR staining on IHC.25 The study 
enrolled patients with documented mCRC disease progres-
sion during or after 2 to 3 regimens of fluoropyrimidine, 
irinotecan, and oxaliplatin treatment. 7% of all patients had 
a PR (low EGFR expression, 8%; negative EGFR expression, 
6%). 29% of all patients had SD (low EGFR expression, Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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29%; negative EGFR expression, 31%), and disease control 
was observed in 37% (low EGFR expression, 39%; negative 
EGFR expression, 37%). The median time to response was 
9 weeks overall and in patients with low and negative EGFR 
expression, with a minimum of 7 weeks and a maximum of 
12 weeks. Median duration of response was 20 weeks (range, 
8–46 weeks) overall. The duration of response was longer in 
patients with negative EGFR expression: 31 weeks (range, 
16–46 weeks) compared with 20 weeks (range, 8–20 weeks) 
in patients with low EGFR expression. Median PFS was 
8 weeks overall (95% CI, 7–11) (low EGFR expression, 
8 weeks (95% CI, 7–13); negative EGFR expression, 7 weeks 
(95% CI, 7–14)).
Objective responses have been observed in patients 
with low or negative, as well as high, EGFR protein 
  expression, thus suggesting that efficacy of panitumumab 
may not depend on the level of EGFR expression. Although 
  immunohistochemistry is widely used, its usefulness in 
predicting the clinical benefit of panitumumab appears 
limited, probably because of several factors like the absence 
of a standardized scoring system and the variety on EGFR 
expression. Therefore, on this basis, the detection of positive 
EGFR expression actually does not reliably predict clinical 
  outcome and requires further validation before incorporation 
into clinical practice.
EGFR findings: affinity, 
phosphorylation, mutations  
and polymorphisms
Several studies investigating other potential predictive 
  biomarkers to EGFR inhibitors response are ongoing. Some 
of these, studied EGFR findings as low or high affinity or 
presence of phosphorylation to explain the variability of 
response to EGFR targeted therapy. In this setting, data exist 
for patients receiving cetuximab while actually we have no 
elements on panitumumab. Using a specific ligand binding 
assay, Francoual et al26 found that many tumors contain both 
low- and high-affinity EGFRs: 78% of 82 tumor specimens 
contained only high-affinity binding sites and 22% had both 
low- and high-affinity sites.
EGFR phosphorylation status may reflect the level of 
receptor utilization by the tumor and this parameter was 
associated with clinical response in patients treated with 
cetuximab-based therapy. Patients with an activated or 
phosphorylated EGFR score, as indicated by an immunohis-
tochemistry-based visual score of 7 or greater, were almost 
twice as likely to have disease control (objective response or 
stable disease) than those with a score of less than 7 (100% 
vs 54%; P = 0.05).27
EGFR mutations in mCRC account for less than 1% of 
tumors, therefore this measure is unlikely to be valid as a 
marker.28 Moreover, EGFR mutations that are associated with 
responses to tyrosine-kinase inhibitors in non-small cell lung 
cancer are not present in mCRC.29,30
Moroni et al detected one mutation (3.2%) among 
31 patients with mCRC,31 occurring in a patient who 
achieved SD for 24 weeks with cetuximab and   chemotherapy 
treatment. This missense heterozygous mutation in exon 
21 (Gly857Arg) affected a residue located within the 
  activation loop of the EGFR catalytic domain and was one 
amino acid away from the Leu858Arg-activating mutation 
that has been identified in patients with lung cancer who 
respond to gefitinib or erlotinib.32 At disease progression, 
the patient whose tumor had this mutation was treated with 
gefitinib; this molecular alteration in EGFR was not associ-
ated with clinical response because the disease progressed 
after 4 weeks of treatment.
Notably, a specific polymorphism of EGFR affecting 
exon 13 at residue 521 Arg/Arg (previously identified as 
residue 497, rs11543848) has been linked with improved 
overall survival in women with metastatic colorectal cancer 
(vs Lys/Lys and/or Lys/Arg variants), although the reverse 
pattern was observed in men with this disease.33 This same 
polymorphism has been linked to cetuximab response in 
other studies34–36 while conflicting evidence also exists for 
a polymorphism affecting the ligand of EGFR, EGF, at 
position 61 (rs4444903).35–38 About panitumumab, data in 
this setting are related to recently analyses. Carcereny et al 
studied a cohort of 84 mCRC patients receiving cetuximab 
or panitumumab. A single nucleotide polymorphism (SNP) 
at codon 497 (497 G/A) was associated with worse RR, PFS 
and OS, and therefore could be a resistance factor.39 More 
recently a retrospectively analyses has not revealed the same 
conclusion of Carcereny et al. In a total of 117 patients treated 
with cetuximab or panitumumab, there were no significant 
differences on response rate (9/59;15.2 vs 9/52; 17.3%), 
PFS (13.5 vs 13.2 w) and OS (33 vs 26.8 w) according to 
EGFR R497K (GG vs GA/AA). Despite, the predictive role 
of K-RAS mutational status was confirmed.40 On this basis, 
actually we have no certain data about these EGFR findings, 
so further investigations need to better define their exact role 
in EGFR inhibitors response.
EGFR amplification
A small proportion of colorectal tumors over-express EGFR 
via amplification of the gene, which can be detected by fluo-
rescence in situ hybridization (FISH) or chromogenic in situ 
hybridization.41 Available data suggest that patients with less Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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than three EGFR gene copies per nucleus have a relatively 
low likelihood of responding to EGFR-targeted monoclonal 
antibody treatment.42–47
Despite when EGFR gene copy number was evaluated by 
polymerase chain reaction, no association was found between 
this parameter and clinical outcome of panitumumab- or 
cetuximab-based treatment,48,49 probably because of tumor 
DNA dilution by DNA from normal cells during DNA 
extraction. However, EGFR gene copy number as analyzed 
by FISH or chromogenic in situ hybridization appears to be 
a promising biomarker of response to such treatment. In a 
retrospective analysis of a subgroup of patients participating 
in the pivotal phase III trial of panitumumab monotherapy,50 
the mean EGFR gene copy number per nucleus and the 
percentage of tumor cells with chromosome 7 polysomy 
(three or more EGFR signals per nucleus) were analyzed by 
FISH and the association between these parameters and clini-
cal outcome was assessed. None of the patients with a mean 
of ,2.47 EGFR gene copies per nucleus or fewer than 43% 
of tumor cells with chromosome 7 polysomy,   respectively, 
achieved objective response compared with 30% of the 
patients (P = 0.001) and 32% of the patients (P = 0.001) 
who had values above these thresholds.
A mean EGFR gene copy number threshold of less 
than 2.5 copies per nucleus or fewer than 40% of tumor 
cells with chromosome 7 polysomy discriminated patients 
with shorter progression-free (P = 0.039 and P = 0.029, 
respectively) and overall survival (P = 0.015 and P = 0.014, 
respectively). EGFR gene copy number and chromosome 7 
polysomy status did not draw a parallel with progression-
free interval in patients receiving only supportive care in 
this study, suggesting that this parameter is not prognostic 
in metastatic colorectal cancer. Homogeneous (ie, 100%) 
chromosome 7 disomy was the most common pattern found 
in 58 colorectal tumors with non increased gene copy number 
(n = 26; 45%). Chromosome 7 disomy is also easier to detect 
than an increase in EGFR gene copy number and therefore, 
might enable a more reproducible FISH assay. For instance, 
Moroni et al31 found a 89% response rate in a subgroup of 
nine patients with colorectal cancer whose tumors had an 
increased EGFR gene copy number, but these investigators 
included a relatively high proportion of responders (9 of 
29 patients; 31%) in their analysis.
In comparison with patients with normal EGFR gene copy 
number, patients with an increased EGFR gene copy number 
exhibit higher response rates to EGFR-targeted monoclonal 
antibodies, with a longer progression-free interval or time to 
progression. These results have to be confirmed by further 
analyses before the incorporation of this promising parameter 
into clinical practice.
EGFR ligands
Several preclinical studies have found that cetuximab 
decreases levels of epiregulin (ER) and amphiregulin (AR) 
that are two EGFR ligands even more powerful than EGF 
for activating EGFR. Therefore the possible predictive roles 
as biomarkers to selecting patients have been investigated 
in trials involving cetuximab.49–52 All data of these studies 
suggest that cetuximab treated patients with high ER and AR 
expression levels obtained a better response rate and PFS. 
Recently the association of a high epiregulin gene expression 
with a K-RAS status wild-type seems to be more predictive 
of cetuximab benefit in the treatment of mCRC than these 
markers analyzed alone. Further studies are needed but 
the authors suggest that determination of epiregulin gene 
expression levels should be prospectively evaluated in patient 
selection for EGFR targeted therapy.53
K-RAS mutations
The K-RAS protein, encoded by K-RAS, is a GTPase that 
  regulates different signaling pathways. This protein may be 
active (RAS-GTP) or inactive (RAS-GDP). K-RAS   mutations 
yield a defective GTPase activity and then an increased 
population of active K-RAS protein, activating signaling in 
two pathways, PI3K/PTEN/AKT and RAF/MEK/ERK which 
are involved in cell proliferation, survival and angiogenesis. 
K-RAS is mutated in approximately 30%–50% of colorectal 
cancer; the most common and clinically relevant K-RAS 
mutations are nonsense somatic alterations which have been 
described at codons 12 (about 82% of cases) and 13 (about 13% 
of cases) in exons 2 of the K-RAS gene; additional   mutations 
can be found at codon 61. All these mutations are associated 
with cancer progression. Recent studies have revealed that 
mutation status of K-RAS has emerged as both an important 
predictor of response to EGFR inhibitors,   including panitu-
mumab, and a marker for patient selection.54
Benvenuti et al analyzed tumor K-RAS status from 
48 patients with mCRC treated with panitumumab or 
cetuximab.55 Presence of K-RAS mutations (exon 2) were 
detected in 33,3% of tumors and it was not significantly 
linked to objective response to therapy, with a trend toward a 
negative association with response (1 of 11 mutations versus 
15 of 37 mutations for responders versus non-responders; 
P = 0.073); consequently time to progression analysis showed 
a significantly worse outcome for subjects bearing a mutated 
K-RAS allele in their tumors compared with those carrying Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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wild-type K-RAS (P = 0.0443). In this study the authors 
also found that the transfection of mutated K-RAS (G12V) 
into wild-type cellular models of colorectal cancer confers 
resistance to the treatment with cetuximab.
A confirm of K-RAS as a predictive marker to therapy 
with panitumumab was reported by Amado et al56 in a 
randomized phase III trial setting. Among the 463 patients 
enrolled in this study, 427 (92%) were included in the K-RAS 
analysis. Of these 427, 184 (43%) were found to have tumors 
harboring mutant K-RAS. Among the 208 patients assigned 
to panitumumab, 17% of the 124 patients in the wild-type 
K-RAS subgroup achieved objective response, whereas none 
of the 84 patients in the mutant K-RAS subgroup responded 
to this treatment. Median progression-free interval among 
those treated with panitumumab was 12.3 weeks among 
those in the wild-type K-RAS subgroup and 7.4 weeks 
among those in the mutant K-RAS subgroup. The OS time 
was also longer in patients with wild-type K-RAS tumors, 
8.1 months, versus 4.9 months. The hazard ratio (HR) for 
disease progression or death (panitumumab vs control group) 
was 0.45 (95% CI = 0.34 to 0.59) for panitumumab in the 
wild-type K-RAS subgroup, but there was no benefit of 
panitumumab in the mutant K-RAS subgroup (HR = 0.99, 
95% CI = 0.73 to 1.36).
Similar findings in term of predictive role of K-RAS 
status to therapy with panitumumab were observed by Hecht 
et al.16 In this study, 171 patient samples were available 
for K-RAS tumor presence. The overall response rate was 
  significantly better in patients with wild-type K-RAS tumors 
(9% vs 0%). Median PFS was significantly longer in patients 
with wild-type K-RAS tumors than in patients with mutant 
K-RAS tumors (15 weeks vs 7.1 weeks, respectively). This 
study also demonstrated a significant benefit in terms of 
OS in patients with wild-type K-RAS tumors treated with 
  panitumumab when compared with patients with mutant 
K-RAS tumors (13.5 months vs 7.3 months, respectively).
Freeman et al retrospectively analyzed 62 patients from 
three phase II studies with panitumumab in mCRC patients.57 
K-RAS mutation was found in 38.7% of them. In the wild-type 
K-RAS group, 11% of patients had a PR, 53% had SD, and 
37% had progressive disease. In the mutant K-RAS group, 
21% of patients had SD and 79% of patients had PD; there 
were no responses. The absence of a K-RAS mutation was 
associated with response to panitumumab (PR vs SD vs pro-
gressive disease; P = 0.0028). The HR for wild-type versus 
mutant K-RAS was 0.4 (95% CI, 0.2–0.7) for progression-free 
survival (PFS) and 0.5 (95% CI, 0.3–0.9) for OS. Second-line 
treatment with panitumumab and FOLFIRI by tumor K-RAS 
status in patients with mCRC was also investigated; in interim 
analyses, numerical significantly differences in PFS (26 vs 
16 weeks) and median OS (39 vs 31 weeks) in favour of 
patients with wild-type K-RAS were observed.58
More recently the efficacy of panitumumab by tumor 
K-RAS status was investigated in some phase III trials. 
  Douillard et al enrolled 1183 patients to evaluate the efficacy 
of FOLFOX-4 with or without panitumumab as first line treat-
ment in patients with mCRC (PRIME trial).21 Results showed 
that the addition of panitumumab to chemotherapy improved 
RR (55% vs 48%) and PFS (9.6 vs 8.0 months; HR = 0.80; 
95% CI: 0.66–0.97; P = 0.02) in patients with wild-type 
K-RAS. No benefit in RR and PFS from the addition of 
panitumumab was noticed in patients with K-RAS mutations. 
Interim OS showed an improvement only for patients with 
wild-type K-RAS tumors (HR = 0.83, P = 0.16).
Similar results were reported in 1186 patients enrolled 
in a randomized phase III study which had the aim to 
evaluate the association of panitumumab with FOLFIRI as 
second-line treatment in patients with mCRC.22 In patients 
with wild-type K-RAS tumors, panitumumab significantly 
improved response rate (35% vs 10%) and PFS (median 5.9 
vs 3.9 mo; HR = 0.73, p = 0.004) when added to FOLFIRI. 
OS was also improved in patients with wild-type K-RAS 
tumors with panitumumab plus FOLFIRI (median 14.5 vs 
12.5 mo; HR = 0.85, P = 0.12).
There was no evidence of benefit in patients with 
mutated K-RAS tumors. In a recently randomised phase 
III trial which evaluated bevacizumab and chemotherapy 
with or without panitumumab in mCRC,20 the predictive 
role of K-RAS   status was confirmed; and progression-free 
interval was worse among patients with tumors carrying 
wild-type K-RAS (11.5 months vs 9.8 months in the pani-
tumumab arm).
A recent exploratory analysis investigating the combina-
tion of panitumumab with FOLFIRI as first line-treatment 
in K-RAS wild-type patients, appears to show improvement 
in PFS and time to disease progression versus the K-RAS 
mutation population.59
As far as cetuximab, across all studies reviewed here, 
it clearly appears that clinical efficacy of panitumumab 
therapy is restricted to patients with wild-type K-RAS 
tumors. Therefore, K-RAS genotyping of tumors should 
be strongly considered to select patients being treated with 
panitumumab.
Further evaluations need to assess the relationship 
between K-RAS mutations and response to panitumumab 
combined with chemotherapy in earlier lines of therapy.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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B-RAF
The B-Raf proto-oncogene serine/threonine-protein kinase 
(B-RAF) is involved in transducing mitogenic signals via the 
MAP kinase/ERK (MAPK) signaling pathway. Mutations in 
B-RAF are involved in mCRC. A thymine to adenine trans-
version mutation results in the substitution of valine with 
glutamate (V600E) and converts B-RAF into a dominant 
transforming protein that causes the constitutive activation 
of the MAPK pathway independently of RAS. The V600E 
B-RAF mutation appears in 4%–15% of CRC.60–62
The possible relationship between of B-RAF mutational 
status and response to treatment with panitumumab in 
48 patients with mCRC was investigated by Benvenuti et al.55 
B-RAF mutations were detected in 12,5% tumors and they 
were mutually exclusive with K-RAS alterations. The only 
B-RAF mutation found was the V600E substitution. The most 
important thing was that patients who received panitumumab 
or cetuximab but had B-RAF alteration, presented no objec-
tive response to therapy; consequently TTP was worse for 
subjects bearing a mutated B-RAF although not statistically 
significant probably due to the limited number of tumors 
carrying these mutations.
More recently Di Nicolantonio et al analysed response 
rate, PFS, OS and the mutational status of K-RAS and B-RAF 
in 113 tumors from cetuximab- or panitumumab-treated 
mCRC patients.63 K-RAS was mutated in 30% of cases and 
B-RAF was mutated in 14% of the K-RAS-wt cases. None 
of the B-RAF mutated patients responded to treatment, and 
none of the responders carried any B-RAF mutations. B-RAF 
mutated patients had a significantly shorter PFS and OS than 
the wild-type cases. Di Nicolantonio et al also demonstrated 
that introduction of the B-RAF V600E allele could confer 
resistance to either cetuximab or panitumumab in wild-type 
B-RAF colorectal cancer cells.
Thus, the low incidence of B-RAF mutations in patients 
with mCRC probably do not permit to select patients who 
have been treated with panitumumab. In clinical practice, a 
B-RAF alteration could explain the resistance to anti-EGFR 
inhibitors in a 10% subpopulation who have K-RAS wild-
type; however, 41% of patients had no mutations in either 
K-RAS or B-RAF and did not respond to therapy, therefore 
other biomarkers are required.
Alternative K-RAS pathways:  
Pi3K, PTEN/AKT
The PIK3CA gene encodes for a lipid kinase that regulates, 
alongside with K-RAS, signaling pathways downstream 
of the EGFR. The PIK3CA gene is mutated in 10%–18% 
of mCRC cases.64,65 PI3K-initiated signaling is normally 
inhibited by phosphatase and tensin homolog deleted on 
chromosome ten (PTEN). Thus, PTEN functions as a tumor 
suppressor gene through the action of its phosphatase protein 
product. The encoded protein negatively regulates intracellu-
lar levels of phosphatidylinositol-3,4,5-trisphosphate (PIP-3) 
in cells and functions as a tumor suppressor by negatively 
regulating the PI3K/AKT signaling pathway. PTEN loss 
increases levels of PIP-3 and PKB/AKT, thus increasing cell 
survival signalling.66,67
Several studies have evaluated the possible role of PI3K 
and PTEN as predictive biomarkers of anti-EGFR drug 
activity, especially in patients receiving cetuximab, but 
data seem more controversial.68–71 In mCRC, it has been 
reported that loss of PTEN expression, which occurs in 30% 
of sporadic cases, may be associated with lack of response 
to cetuximab.
Our present knowledge of the active pathways for pani-
tumumab is based on a single study conducted by Sartore-
Bianchi.72 In this analysis, mutational profiling of 110 CRC 
tumors from patients receiving cetuximab or panitumumab 
led to the identification of 13.6% PIK3CA and 29.0% K-RAS 
mutations. The study showed that mutations in PIK3CA, 
K-RAS, and PTEN loss were associated with lack of 
  objective response to panitumumab or cetuximab. PIK3CA 
mutations were significantly associated with lack of response 
to panitumumab or cetuximab, with none of the mutated 
patients achieving objective tumor response (P = 0.038).
The same negative association was confirmed for K-RAS 
mutations (9.1% of mutations among responders versus 
34.5% among non responders; P = 0.019) and was con-
firmed when at least a mutation of either K-RAS or PIK3CA 
was considered (P = 0.001). Consequently patients with 
tumors harboring PIK3CA mutations had a worse clinical 
outcome in terms of PFS, compared with wild-type tumors 
(P = 0.0035). Patients with K-RAS mutations had a trend 
toward a decreased PFS (P = 0.0815). Shorter PFS was also 
detected in patients harboring at least a mutation of either 
K-RAS or PIK3CA (P = 0.0032).
Despite the results of this study, further investigation is 
needed to establish the effective roles of PI3K and PTEN/
AKT as predictive biomarkers to selecting patients who 
could have be treated with EGFR inhibitors, including 
panitumumab.
Other potential biomarkers
Increased gene copy number of HER2 (the preferred het-
erodimer of EGFR) was linked to a statistically significantly Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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shorter overall survival (P = 0.03), with a trend toward a 
shorter time to progression (P = 0.09), in 85 patients receiv-
ing cetuximab with or without chemotherapy.73
The interaction between IGF-1 expression and K-RAS 
mutational analysis was also tested in order to verify the ability 
of IGF-1 to identify a sub-group of patients more likely to benefit 
from EGFR-targeted antibodies treatment.74 Among K-RAS 
wild type patients, median time to progression in IGF-1 negative 
tumors was 11 months and 3.2 months in IGF-1 positive CRC (P 
= 0.03). IGF-1 proved to be a reliable predictive factor for resis-
tance to anti-EGFR monoclonal antibodies in K-RAS wild type 
CRC. Thus combined IGF-1 and K-RAS analysis may represent 
an effective strategy for a better selection of responding CRCs in 
this setting. Other potential mechanisms of acquired resistance 
to EGFR inhibitors, such as those involving activation HER3, 
mesenchymal-epithelial transition factor (C-MET), MAPK, 
AKT, VEGF, IL8, COX-2 and Cyclin D are under investigation 
in patients with mCRC receiving EGFR inhibitors but data on 
their use in selecting patients are not available.75–77
Skin toxicity
Skin toxicity is most frequently seen as acneiform rash 
  generally confined to the seborrhoeic areas; this particularly 
toxicity is a characteristic finding seen with most EGFR inhibi-
tors, including panitumumab. It appears to be dose-related and 
may indicate EGFR saturation, given the high expression of 
this receptor in keratinocytes skin fibroblasts and hair follicles. 
Skin rash observed in most patients who have been treated 
with EGFR inhibitors has been studied as a potential marker 
of efficacy. Skin toxicity has been significantly linked with 
higher response rate and longer survival in several trials with 
patients with mCRC and treated with cetuximab.
Longer PFS and OS were significantly observed in patients 
with worst skin toxicity of grade 2–4 compared with those 
with at worst grade 1.78,79 The association between skin tox-
icity and PFS was only seen for panitumumab patients with 
wild-type K-RAS. No association between skin toxicity and 
PFS was seen in the mutant K-RAS group. Of note, a higher 
incidence of grade 3 skin toxicity was observed in patients 
with wild-type K-RAS tumors as compared with mutant 
K-RAS, consistent with longer time on treatment. The associa-
tion of OS with skin toxicity severity was more pronounced 
for the wild-type K-RAS than the mutant K-RAS group.
Berlin et al conducted a pooled analysis of five clinical tri-
als which involved a total of 612 patients with mCRC treated 
with panitumumab.80 They showed better overall response 
rate, PFS, and OS in patients who developed a grade 2–4 skin 
toxicity than in patients with grade 0–1 skin toxicity.
Although there is some evidence that skin toxicity 
  represents a marker of clinical benefit in patients treated with 
panitumumab, its utility in the clinical setting is limited, as it 
cannot be used a priori to select patients who may derive greater 
benefit from anti-EGFR treatment, or conversely, exclude those 
who may not. Potentially, however, this marker could be used 
clinically to titrate treatment doses to achieve a skin toxicity 
grade consistent with maximum treatment benefit.
Economic evidence
Because of substantial increase in costs, physicians need to 
consider the cost-effectiveness of new therapies as well as the 
clinical issues. Consideration of a treatment’s cost effective-
ness can help to avoid therapies that produce too little benefit 
at too high a cost.
More progress has been made in increasing the duration 
of survival in patients with mCRC in the past 5 years than in 
most other cancers. Although the introduction of better sys-
temic therapy and novel therapeutic agents has considerably 
improved the prognosis in this setting, these potential clinical 
benefits caused escalating drug costs. The near-doubling of 
the median survival time achieved over the past decade has 
been accompanied by a 340-fold increase in drug costs for 
the initial 8 weeks of therapy alone.81 Many countries are 
experiencing increased pressure on their budgets to finance 
these therapies.
Conversely, Paramore et al showed that the economic 
impact of mCRC is substantial and increasing over time, and 
that monthly cost almost tripled from 1998 to 2004.82 Large-
scale economic analyses reported that employing cetuximab 
in patients with metastatic colorectal cancer is clinically 
effective but associated with high costs per life year.
Regarding panitumumab, the average wholesale price for 
panitumumab (20 mg/mL 20 mL vial) is US $4000. Therefore, 
the cost of therapy for a 60 kg patient is about $8000/month.
A recent Italian treatment costs analysis to evaluate the 
safety of panitumumab comparing with cetuximab in third line 
mCRC, identified savings per patient of 111 euro per month.83 
The safety savings were 50 euro per month and the adminis-
tration savings were 690 euro per month,   giving a combined 
saving of 851 euro. Treatment cost savings   associated with 
panitumumab were related to a low rate of severe infusion 
reaction versus cetuximab, reduced hospital costs associated 
with a less frequent dosing regimen and patients’ weight savings 
across a normally distributed patient population. Based on the 
calculated prevalence and the assumption of a 4 month treat-
ment period, panitumumab is modeled to provide savings of 
7.67 million euro/year to the Italian healthcare system compared Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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with cetuximab. Reduced drug costs and further improvements 
in clinical effectiveness may alter this finding.84,85
Moreover, K-RAS mutational status has emerged as 
an important biomarker for mCRC and should be assessed 
before patients begin therapy.86 Because K-RAS status can 
aid in therapy selection, oncologists can avoid unnecessary 
toxicities and expenses related to patients unlikely to respond. 
A recent study by Mancl et al reviewed the clinical use of 
cetuximab and panitumumab and the role of K-RAS testing in 
clinical practice.87 A simple breakeven analysis using a group 
of 100 hypothetical patients with metastatic colorectal cancer 
revealed that Preemptive K-RAS screening had tremendous 
cost-saving potential.
Screening could cost several thousand dollars per patient 
and still result in a lower overall cost of care, based on very 
conservative estimates of the cost reduction associated with 
treatment avoidance in patients with K-RAS mutations. 
Moreover, because EGFR inhibitors are indicated as third-
line therapy for metastatic colorectal cancer, few options exist 
for patients who do not respond to treatment or have mutant 
K-RAS. Such patients will most likely receive best supportive 
care or choose to enroll in a clinical trial.87
Implementing routine K-RAS screening and limiting 
the use of EGFR inhibitors to patients with wild-type (not 
mutated) K-RAS may have the potential for cost savings.
Conclusions
The evidence to hand and the implications of these are 
  summarized from the above discussion into clinical impact 
summary.
Intravenous panitumumab has been approved as monotherapy 
for the treatment of adult patients with chemotherapy-  refractory, 
EGFR-expressing, mCRC with non mutated K-RAS.
The improvement in PFS and RR produced by panitumumab 
monotherapy was significantly greater in patients with non 
mutated (wild-type) K-RAS than in those with mutant K-RAS 
in whom no benefit from panitumumab was observed.
The predictive value of mutant K-RAS for a lack of 
clinical benefit with panitumumab monotherapy was sup-
ported and also confirmed by results recently from some 
phase II–III studies. Therefore K-RAS status evaluation is 
the only sure predictive biomarker of response that have 
to be investigated before starting a therapy with EGFR-
inhibitors in patients with mCRC. Thus implementing 
routine K-RAS screening and limiting the use of EGFR 
inhibitors to patients with wild-type K-RAS appears the 
better strategy for selecting only patients who could benefit 
from the therapy with panitumumab and also may have the 
potential for significant cost savings while improving positive 
outcomes for patients.
Uncertain data are about new biomarkers, such as B-RAF 
or PTEN, which may play a role in predictive response, that 
will further narrow the selection of mCRC patients.
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